60798-08-5Relevant articles and documents
Efficient green OLEDs achieved by a terbium(III) complex with photoluminescent quantum yield close to 100%
Zhao, Zifeng,Bian, Mengying,Lin, Chenjian,Fu, Xuzheng,Yu, Gang,Wei, Huibo,Liu, Zhiwei,Bian, Zuqiang,Huang, Chunhui
, p. 1504 - 1509 (2021)
Electroluminescence of f-f transition lanthanide complex is a traditional topic for display over decades. Here we report highly efficient organic light-emitting diodes based on a new terbium(III) complex with novel ligand CPMIP (1-(4-cyanophenyl)-3-methyl-4-isobutyryl-pyrazoline-5-one). The high triplet energy level of CPMIP (3.0 eV) and inhibited quenching effects in the solid-state lead to a nearly 100% photoluminescent quantum efficiency of Tb(CPMIP)3. The best Tb(CPMIP)3 device exhibited maximum external quantum efficiency up to 19.7%, setting a new record of OLEDs based on f-f transition lanthanide complexes. [Figure not available: see fulltext.].
Histone acetyltransferase P300 small molecule inhibitor and medicinal composition and application thereof
-
Paragraph 0054-0058, (2020/03/17)
The compound capable of inhibiting histone acetyltransferase, has a significant inhibition effect p300 in inhibiting the activity, of the histone acetyltransferase, or a pharmaceutically acceptable salt (I) of; has a significant inhibitory effect on tumor cells such as the primary, representative small molecule inhibitor p300 to prostate cancer cells, malignant blood tumor cells p300 breast cancer cells, and has an effect of inhibiting the toxicity C646, of the compound by overcoming the defects, of the original, small molecule inhibitor, existing in the present invention. C646 p300. The compounds of the formula C646; are shown in, Table (I). The invention belongs to, the field of pharmaceutical chemistry.
Structure-activity relationships of pyrazole-4-carbodithioates as antibacterials against methicillin–resistant Staphylococcus aureus
Majed, Hiwa,Johnston, Tatiana,Kelso, Celine,Monachino, Enrico,Jergic, Slobodan,Dixon, Nicholas E.,Mylonakis, Eleftherios,Kelso, Michael J.
supporting information, p. 3526 - 3528 (2018/10/15)
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of serious hospital-acquired infections and is responsible for significant morbidity and mortality in residential care facilities. New agents against MRSA are needed to combat rising resistance to current antibiotics. We recently reported 5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC) as a new bacteriostatic agent against MRSA that appears to act via a novel mechanism. Here, twenty nine analogs of HMPC were synthesized, their anti-MRSA structure-activity relationships evaluated and selectivity versus human HKC-8 cells determined. Minimum inhibitory concentrations (MIC) ranged from 0.5 to 64 μg/mL and up to 16-fold selectivity was achieved. The 4-carbodithioate function was found to be essential for activity but non-specific reactivity was ruled out as a contributor to antibacterial action. The study supports further work aimed at elucidating the molecular targets of this interesting new class of anti-MRSA agents.
